Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Polyclonal Tregs for Lupus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02428309
Recruitment Status : Terminated (Due to participant recruitment feasibility)
First Posted : April 28, 2015
Results First Posted : November 12, 2019
Last Update Posted : November 12, 2019
Sponsor:
Collaborator:
Autoimmunity Centers of Excellence
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus. Targeting cutaneous disease offers the ability to control background therapy, readily detect clinical effects, and perform research analyses not only in blood but also skin. Safety, disease activity, and mechanism of Tregs will be evaluated. The intent is to support dose selection for a future larger efficacy trial in lupus.

Condition or disease Intervention/treatment Phase
Lupus Erythematosus, Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells Phase 1

Detailed Description:
The investigational therapy in this trial, regulatory T cells (Tregs), is evaluating an alternative to traditional immunosuppressive therapies for the treatment of systemic lupus erythematosus (SLE, lupus). Too frequently, aggressive therapies are inadequate in the control of the disease and have potent side effects and complications. The collection and expansion of one's own T cells harnesses a naturally occurring regulatory mechanism to restore self-tolerance in people with lupus. Tregs are a specialized subset of T cells that function to control the immune response. Studies have shown that in active lupus, the numbers and function of Treg cells are significantly decreased, which contributes to an overactive immune system and an increase in disease activity. The hope is that these naturally occurring Treg cells can be used for the treatment of autoimmune diseases, including lupus.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08)
Actual Study Start Date : August 27, 2015
Actual Primary Completion Date : September 2, 2016
Actual Study Completion Date : October 3, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: Low Dose Treg Cohort
3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Other Name: Ex vivo Expanded Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T Cells

Experimental: Medium Dose Treg Cohort
Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Other Name: Ex vivo Expanded Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T Cells

Experimental: High Dose Treg Cohort
Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Other Name: Ex vivo Expanded Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T Cells




Primary Outcome Measures :
  1. Number of Significant Adverse Events (AEs) Through Week 48 [ Time Frame: From time of signed informed consent to Week 48 ]
    A significant adverse event is any related National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0 Grade 3 or higher AE or any related serious adverse event. Related is defined as being possibly, probably, or definitely related to the ex vivo expanded autologous PolyTregs, as determined by the safety review committee.


Secondary Outcome Measures :
  1. Number of Significant Adverse Events (AEs) Through Week 152 [ Time Frame: From time of signed informed consent to Week 152 ]
    A significant adverse event is any related National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0 Grade 3 or higher AE or any related serious adverse event. Related is defined as being possibly, probably, or definitely related to the ex vivo expanded autologous PolyTregs, as determined by the safety review committee.

  2. Number of Grade 3 or Higher Adverse Events (AEs) Through Week 152 [ Time Frame: From time of signed informed consent to Week 152 ]
    Adverse events (AEs) Grade 3 or higher were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0.

  3. Number of Infection-Related Adverse Events (AEs) Through Week 152 [ Time Frame: From time of signed informed consent to Week 152 ]
    If the adverse event was believed to be caused by a viral, bacterial, or fungal organism, regardless of whether it was treated with antibiotics or not, then it was classified as infection-related.

  4. Number of Lupus Flares Through Week 152 by Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Criteria [ Time Frame: From time of signed informed consent to Week 152 ]
    An activity score increase of ≥4 CLASI points defines a flare. A mild/moderate flare includes at least one of the following SELENA-SLEDAI criteria: Increase in the SLEDAI Score of ≥3 points, new or worse discoid, photosensitive, profundus, cutaneous vasculitis, bullous lupus, nasopharyngeal ulcers, pleuritic, pericarditis, arthritis, fever attributable to SLE; increase in prednisone (<0.5 mg/kg/day); added NSAID or Plaquenil; increase in PhGA (<2.5 [on a 3.0 indexed VAS scale]). A severe flare includes at least one of the following SELENA-SLEDAI criteria: Increase of >12 in the SLEDAI Score; new or worse CNS-SLE, vasculitis, nephritis, myositis, platelet count <60,000/mm^3, hemolytic anemia with hemoglobin <7% or decrease in hemoglobin >3%; prednisone >0.5 mg/kg/day; new Cyclophosphamide, Azathioprine, Methotrexate, Mycophenolate Mofetil, or hospitalization attributable to SLE; increase in PhGA to >2.5.

  5. Number Infusion-Related Adverse Events (AEs) Within 24 Hours of Infusion [ Time Frame: From time of infusion to 24 hours post infusion ]
    Any infusion-related adverse events Grade 1 or higher within 24 hours of polyclonal Treg infusion. This study graded the severity of adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0.

  6. Change From Baseline: Alkaline Phosphatase (ALK), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values are based on subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  7. Change From Baseline in g/dL: Albumin, Hemoglobin [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  8. Change From Baseline in mg/dL: Total Bilirubin, Creatinine [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  9. Change From Baseline in mmol/L: Potassium, Sodium, Chloride [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  10. Change From Baseline in Cell Counts: White Blood Cells (WBC), Total Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  11. Change From Baseline Red Blood Cell Count [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  12. Change From Baseline in mm/hr: Sedimentation Rate (ESR) [ Time Frame: Baseline (Visit 0) and Weeks 4, 12, 48, and 152 ]
    Change=Post Baseline value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values.

  13. Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated, physician-based assessment tool used to measure cutaneous lupus severity. Severity is calculated based on disease activity (erythema and scale) and damage (dyspigmentation and scarring) for the cumulative areas of involved skin. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70). A 4-point or 20% change in the CLASI activity score identifies a clinically meaningful change. A 4-point increase in the CLASI activity score indicates a flare.

  14. Change From Baseline in SELENA-SLEDAI Total Score [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    The Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus (SLE) Disease Activity Index (SELENA-SLEDAI) score is a weighted scale score ranging from 0 to 105 based on the presence or absence of 24 manifestations of SLE. The SELENA-SLEDAI assesses disease activity for 10 days prior to and including the day of assessment. Positive change in the SELENA-SLEDAI score indicates increased disease activity.

  15. Change From Baseline in Patient's Global Assessment (PGA) [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    The global assessment (PGA) is a visual 3-inch analog scale from 0 to 3 in which the participant marks the scale according to perceived disease activity. A score of 0 corresponds to no lupus disease activity and a score of 3 corresponds to severe disease activity. A positive change from baseline indicates more disease activity.

  16. Change From Baseline in Physician's Global Assessment (PhGA) [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    The physician's global assessment (PhGA) is a visual analog 3-inch scale in the SELENA-SLEDAI that is scored from 0 to 3 by the physician. A score of 0 corresponds to no lupus disease activity and a score of 3 corresponds to severe disease activity. A positive change from baseline indicates more disease activity.

  17. Change From Baseline in Anti-dsDNA Antibody Titers [ Time Frame: Baseline ( Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    Double-stranded DNA is one of multiple diagnostic tests for SLE and high levels may be associated with disease activity. The positive range is based on the normal range from the local laboratory. A positive change from baseline value indicates the detection of autoantibodies to double-stranded DNA.

  18. Change From Baseline in Serum C3 Complement Levels [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    C3 is a blood test that measures the activity of the complement component 3 (C3) protein. The normal C3 range is 71 to 159 mg/dL. Those with active systemic lupus erythematosus (SLE) may have a lower-than-normal level of C3. A decrease in C3 level over time may indicate SLE disease activity.

  19. Change From Baseline in Serum C4 Complement Levels [ Time Frame: Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152 ]
    C4 is a blood test that measures the activity of the complement component 4 (C4) protein. The normal range is 13 to 30 mg/dL. Individuals with active systemic lupus erythematosus (SLE) may have a lower-than-normal level of C4. A decrease in C4 level over time may indicate disease activity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to provide informed consent.
  • Diagnosis of SLE by American College of Rheumatology (ACR) criteria or biopsy proven primary cutaneous lupus.
  • Presence of ≥ 2 active cutaneous lupus lesions based on (1) visual morphology and (2) at least a grade 2 erythema on CLASI activity score. Histopathologic confirmation is required unless the active lesions are of the same morphology to previously histologically proven cutaneous lupus lesions.
  • The cutaneous lupus lesions must include any of the following subtypes:

    • Acute cutaneous lupus including maculopapular lupus rash and photosensitive lupus rash,
    • Subacute cutaneous lupus,
    • Chronic cutaneous lupus including discoid lupus and hypertrophic (verrucous) lupus,
    • Lupus timidus
  • Positive test for Epstein-Barr virus (EBV) antibody.
  • Adequate venous access to support draw of 400 mL whole blood and infusion of investigational therapy.

Exclusion Criteria:

  • New onset of cutaneous lupus which has not been treated with broad spectrum sunscreen (UVA and UVB) in combination with either antimalarials or another systemic medication for at least 3 months.
  • Prednisone dose > 15mg/day within the 30 days prior to screening.
  • Addition of a new medication, or change in the dose of any background medication, used to treat any aspect of SLE. Specifically:

    • addition or change in systemic glucocorticoids, antimalarials, methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, tacrolimus, thalidomide, lenalidomide, dapsone, acitretin, or isotretinoin within 90 days prior to screening
    • treatment with cyclophosphamide within 90 days prior to screening.
  • Doses of background medications at Screening visit:

    • hydroxychloroquine > 400 mg/day,
    • chloroquine > 250 mg/day,
    • quinacrine >100 mg/day,
    • methotrexate > 25 mg/week,
    • mycophenolate mofetil (MMF)> 3000 mg/day,
    • mycophenolic acid > 720 mg/day BID,
    • azathioprine > 200 mg/day,
    • cyclosporine > 5 mg/day divided BID,
    • tacrolimus > 6 mg/day
    • thalidomide > 300 mg/day,
    • lenalidomide > 10 mg/day,
    • dapsone > 250 mg/day,
    • acitretin > 50 mg/d (or > 1 mg/kg/day),
    • isotretinoin > 120 mg/d (or > 2 mg/kg/day).
  • Intravenous immunoglobulin (IVIG), plasmapheresis, or leukopheresis within the 90 days prior to screening.
  • Use of rituximab within the 12 months prior to screening.
  • Change in dosing frequency, concentration, or applied surface area of topical steroids, tacrolimus, and/or pimecrolimus within 4 weeks prior to screening.
  • Active severe central nervous system lupus.
  • SELENA-SLEDAI's seizure, psychosis, organic brain syndrome, visual disturbance,cranial nerve disorder, lupus headache, cerebrovascular accident (CVA), vasculitis,arthritis, myositis, mucosal ulcers, pleurisy, pericarditis, and fever scores > 8 total.
  • Active lupus nephritis (spot protein / creatinine ratio > 1.0 mg/mg).
  • End stage renal disease (estimated glomerular filtration rate [eGFR] < 20 ml/min/1.73m^2 using the CKD-EPI equation [53]).
  • Drug induced lupus.
  • Hemoglobin < 10 g/dL.
  • White blood cell (WBC) count < 2,500/ mm^3 (equivalent to < 2.5 x10^9/L).
  • Lymphocyte count < 625/mm^3 (equivalent to < 0.625 x10^9/L).
  • Absolute neutrophil count < 1,500/mm3 (equivalent to < 1.5 x10^9/L).
  • Platelets < 75,000/mm^3 (equivalent to < 75 x 10^9/L).
  • Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT], or alkaline phosphatase [ALK]) results that are ≥ 2 times the upper limit of normal (ULN).
  • Direct bilirubin > ULN.
  • Active bacterial, viral, fungal, or opportunistic infections requiring systemic antiinfective therapy.
  • Presence of positive purified protein derivative tuberculin skin test (PPD, > 5mm induration [regardless of Bacille Calmette Guerin (BCG) vaccine administration]) or positive or indeterminate QuantiFERON(R)-TB Gold In-Tube Test (QFT-G_IT) at screening.
  • Evidence of infection with human immunodeficiency virus (HIV), hepatitis B (as assessed by HBsAg and anti-HBc) or hepatitis C.
  • Detectable circulating EBV or cytomegalovirus (CMV) genomes or active infection.
  • Chronic infection that is currently being treated with suppressive anti-infective therapy, including but not limited to tuberculosis, pneumocystis, CMV, herpes zoster, and atypical mycobacteria.
  • Herpes simplex virus infection requiring chronic, suppressive therapy with an anti-viral medication.
  • Receipt of a live-attenuated vaccine within 12 months prior to screening.
  • Concomitant malignancies or a history of malignancy, with the exception of adequately treated basal and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • Pregnancy.
  • Breastfeeding.
  • Unwilling or unable to use reliable method(s) of contraception from four weeks prior to Day 0 throughout three months after Treg dosing (males) or for two years after Treg dosing (females). Note: investigators of female participants of childbearing potential on concurrent MMF, and those participants themselves, whether or not they plan to become pregnant, are strongly encouraged to participate in Mycophenolate Risk Evaluation and Mitigation Strategy (REMS).
  • Use of an experimental therapeutic agent within the calendar year prior to screening.
  • Use of biologic medications other than rituximab within the 90 days or 5 half-lives,whichever is greater, prior to screening.
  • Concomitant medical condition that places the subject at risk by participating in this study, including but not limited to:

    • another severe, systemic autoimmune disease or condition (besides lupus) requiring systemic immunosuppressive therapy (e.g., rheumatoid arthritis, systemic sclerosis, primary Sjogren's syndrome, primary vasculitis, psoriasis, multiple sclerosis, ankylosing spondylitis, and inflammatory bowel disease), or
    • severe, progressive, or poorly controlled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease, either related or unrelated to SLE, or
    • history of significant infection or recurrent infection that, in the investigator's opinion, places the subject at risk by participating in this study
    • any other concomitant medical condition that, in the investigator's opinion, places the subject at risk by participating in this study.
  • Comorbidities requiring glucocorticoid therapy, including those which have required three or more courses of systemic glucocorticoids within the previous 12 months.
  • Current or history within the past year of substance abuse.
  • Inability to comply with study and follow-up procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02428309


Locations
Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmunity Centers of Excellence
Investigators
Layout table for investigator information
Study Chair: Maria Dall'Era, MD University of California, San Francisco
Study Chair: Anna Haemel, MD University of California, San Francisco
Study Chair: Jeffrey Bluestone, PhD University of California, San Francisco
Study Chair: Michael Rosenblum, MD, PhD University of California, San Francisco
Study Chair: David Wofsy, MD University of California, San Francisco
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT02428309    
Other Study ID Numbers: DAIT ALE08
First Posted: April 28, 2015    Key Record Dates
Results First Posted: November 12, 2019
Last Update Posted: November 12, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The plan is to share participant level data and additional relevant materials in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts. Currently: study in progress-no data sharing.
Time Frame: The aim is to share data available to the public within 24 months upon completion of the study.
Access Criteria: Will be available to the public.
URL: http://www.immport.org/immport-open/public/home/home
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
active cutaneous lupus
systemic lupus erythematosus (SLE)
autologous polyclonal regulatory T cell Therapy
polyclonal Tregs for treatment of lupus
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Discoid
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Skin Diseases